---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pioglitazone and vitamin E"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pioglitazone and vitamin E. Topics: AASLD practice guidance statements: pioglitazone and vitamin E; AASLD update to the practice guidance on resmetirom: regulatory status of pioglitazone and vitamin E for MASH; EASL-EASD-EASO guideline recommendations: pioglitazone and vitamin E not recommended as MASH-targeted therapies; ADA Standards of Care recommendations 4.27a, 4.27b, and 4.30a: pioglitazone in adults with type 2 diabetes and MASH; 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/pioglitazone-and-vitamin-e"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pioglitazone and vitamin E

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Pioglitazone and Vitamin E

<a id="topic-2.2.2.1.4-1"></a>

### AASLD practice guidance statements: pioglitazone and vitamin E

> “Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM”
> “Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes”
> “Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and these compounds have not been carefully studied in patients with cirrhosis”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.4-2"></a>

### AASLD update to the practice guidance on resmetirom: regulatory status of pioglitazone and vitamin E for MASH

> “AASLD guidance previously recognized that in the absence of approved therapy, pharmacologic treatment with semaglutide, pioglitazone, and vitamin E could be considered in appropriate patients.”
> “Although not FDA approved for the treatment of MASH, vitamin E and pioglitazone may also improve steatohepatitis.”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.4-3"></a>

### EASL-EASD-EASO guideline recommendations: pioglitazone and vitamin E not recommended as MASH-targeted therapies

> “Where available, pioglitazone is safe to use in adults with non-cirrhotic MASH but given the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis in large phase III trials, pioglitazone cannot be recommended as a MASH-targeted therapy (LoE 2, weak recommendation, consensus).”
> “Given the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis derived from large phase III trials and potential long-term risks, vitamin E cannot be recommended as a MASH-targeted therapy (LoE 2, weak recommendation, strong consensus).”
> “However, no large, international, phase III trial has been conducted and pioglitazone has been withdrawn from the market in several European countries.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.4-4"></a>

### ADA Standards of Care recommendations 4.27a, 4.27b, and 4.30a: pioglitazone in adults with type 2 diabetes and MASH

> “In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.”
> “Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH. B”
> “In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH. B”
> “In the context of treating hyperglycemia in individuals with type 2 diabetes with MASLD, where the low cost of pioglitazone and any liver improvement would be an added benefit to glycemic management, these plans would be potentially cost-effective for the treatment of MASLD”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.4-5"></a>

### ADA Standards of Care: vitamin E with and without type 2 diabetes

> “Vitamin E may be beneficial for the treatment of MASH in individuals without diabetes”
> “However, in individuals with type 2 diabetes, vitamin E monotherapy was found to be ineffective in a small RCT”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.4-6"></a>

### PIVENS: pioglitazone 30 mg or vitamin E 800 IU vs placebo in 247 adults without diabetes, 96 weeks, intention-to-treat primary analysis

> “We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks.”
> “The primary analysis was an intention-to-treat analysis in which the proportions of subjects in each active-treatment group (pioglitazone and vitamin E) in whom there was improvement in nonalcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement.”
> “Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P = 0.04).”
> “both agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for vitamin E and P = 0.12 for pioglitazone).”

Source: [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/)

<a id="topic-2.2.2.1.4-7"></a>

### PIVENS: resolution of steatohepatitis with pioglitazone, as summarized in the AASLD practice guidance

> “In the PIVENS trial, pioglitazone treatment did not meet the a priori primary endpoint of a ≥2-point reduction NAS without worsening of fibrosis, although 47% had NASH resolution compared with 21% of participants receiving placebo (p <0.001)”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.4-8"></a>

### Pioglitazone 45 mg/d for 18 months in 101 randomized participants with NASH and prediabetes or type 2 diabetes

> “Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics.”
> “All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment.”
> “Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each).”
> “Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039)”
> “The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).”
> “Single-center study.”

Source: [Cusi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27322798/)

<a id="topic-2.2.2.1.4-9"></a>

### Pioglitazone safety: weight gain, heart failure, fractures, and bladder cancer in guideline texts

> “Potential side effects associated with pioglitazone include weight gain, osteoporosis in postmenopausal women, a debated risk of bladder cancer, and potential risk for worsening heart failure in those with preexisting cardiac dysfunction”
> “its use in clinical practice has been overtaken by the increasing use of newer antidiabetic agents such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) with pleiotropic metabolic benefits, most notably weight loss and reduction in cardiovascular mortality”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “Pioglitazone causes dose-dependent weight gain (15 mg/day, mean weight gain of 1–2%; 45 mg/day, mean weight gain of 3–5%), which can be blunted or reversed if combined with SGLT2 inhibitors or GLP-1 RAs”
> “Pioglitazone increases fracture risk, may promote heart failure if used in individuals with preexisting congestive heart failure, and may increase the risk of bladder cancer, although this remains controversial”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

> “but the side effect profile (weight gain, pedal oedema, haemodilution, bone loss in post-menopausal women and a debate around the risk of bladder cancer) has limited its development for MASH”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.4-10"></a>

### Pioglitazone safety: boxed warning for congestive heart failure in the FDA label

> “Thiazolidinediones, including ACTOS, cause or exacerbate congestive heart failure in some patients”
> “ACTOS is not recommended in patients with symptomatic heart failure.”
> “Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated”

Source: [Takeda Pharmaceuticals ACTOS prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf)

<a id="topic-2.2.2.1.4-11"></a>

### Pioglitazone safety in PIVENS: weight gain at week 96 and cardiovascular events

> “There was a significant improvement in insulin resistance only in the pioglitazone group, but that group was also the only group that had a significant mean weight gain (a mean increase of 4.7 kg at week 96, P<0.001 for the comparison with placebo)”
> “A similar number of cardiovascular events occurred among subjects taking placebo (12 events), those taking vitamin E (12), and those taking pioglitazone (10). No cases of congestive heart failure were reported.”

Source: [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/)

<a id="topic-2.2.2.1.4-12"></a>

### Vitamin E safety and advanced fibrosis outcomes in the AASLD practice guidance

> “Although no study has demonstrated that vitamin E meaningfully reduces fibrosis, a retrospective study of 236 patients with NASH and advanced fibrosis showed that vitamin E use was associated with lower rates of hepatic decompensation (37% vs. 62%, p = 0.04) and higher transplant free survival (78% vs. 49%, p < 0.01)”
> “Concern about the risks of vitamin E on bleeding and specifically hemorrhagic stroke has been raised, but prospective data are needed to confirm this observation.”
> “In addition, data demonstrating a relationship between vitamin E and prostate cancer are conflicting”
> “Such potential risks should be discussed with patients before initiation of long-term high-dose (eg, 800 IU daily) vitamin E therapy.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

Additional sources: [Cusi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35569886/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
